13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001858703
Total reported value
$664.5M
$664.5M
73 檔
22.5%
As reported in its official Q1 2025 Form 13F filing, Blue Owl Capital Holdings LP's tracked investment portfolio stood at $664.5M with 73 total positions.
In Q1 2025, Blue Owl Capital Holdings LP displayed an active expansion posture, initiating 7 new positions and adding to 16 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | NCDL | Nuveen Churchill Direct Lend | Stock-Other | 22.12% | -3.32% | — | |
| 2 | OBDC | Blue Owl Capital CORP | Stock-Financials | 9.67% | -2.73% | — | |
| 3 | CGEM | Cullinan Therapeutics Inc | Stock-Other | 5.95% | -3.07% | +2.74% | |
| 4 | EVCM | Evercommerce Inc | Stock-Other | 5.34% | — | — | |
| 5 | TRML | Tourmaline Bio Inc | Stock-Other | 5.09% | — | -3.91% | |
| 6 | CNDT | Conduent Inc | Stock-Other | 4.96% | -0.62% | +1.28% | |
| 7 | ✓ | Engene Holdings Inc | Stock-Other | 4.74% | -8.08% | EXIT | |
| 8 | HLLY | Holley Inc | Stock-Other | 4.41% | -1.81% | +77.84% | |
| 9 | LRMR | Larimar Therapeutics Inc | Stock-Other | 3.31% | -4.40% | +2.69% | |
| 10 | TQQQ | Proshares Ultrapro Qqq | ETF-Other | 3.23% | — | — | |
| 11 | CVEO | Civeo CORP | Stock-Other | 2.58% | -1.28% | EXIT | |
| 12 | IRON | Disc Medicine Inc | Stock-Other | 2.25% | — | +16.63% | |
| 13 | ELDN | Eledon Pharmaceuticals Inc | Stock-Other | 1.99% | -0.84% | -7.14% | |
| 14 | CMPX | Compass Therapeutics Inc | Stock-Other | 1.81% | -2.99% | — | |
| 15 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 1.79% | -0.78% | +29.60% | |
| 16 | ✓ | Ikena Oncology Inc | Stock-Other | 1.69% | — | — | |
| 17 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 1.46% | — | +43.18% | |
| 18 | CNTX | Context Therapeutics Inc | Stock-Other | 1.45% | -3.34% | +15.89% | |
| 19 | SGMT | Sagimet Biosciences Inc-a | Stock-Other | 1.40% | +1.00% | +0.34% | |
| 20 | EYPT | Eyepoint Inc | Stock-Other | 1.39% | -1.52% | +19.47% | |
| 21 | PLRX | Pliant Therapeutics Inc | Stock-Other | 1.29% | -1.01% | EXIT | |
| 22 | PVLA | Palvella Therapeutics Inc | Stock-Other | 1.27% | -0.22% | -43.91% | |
| 23 | RPTX | Repare Therapeutics Inc | Stock-Other | 1.09% | — | — | |
| 24 | ETWOGBP | E2open Parent Holdings Inc | Stock-Other | 1.06% | — | — | |
| 25 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 1.06% | — | — | |
| 26 | CMPS | Compass Pathways PLC | Stock-Other | 1.05% | +0.96% | NEW | |
| 27 | TNGX | Tango Therapeutics Inc | Stock-Other | 0.94% | — | +22.49% | |
| 28 | KROS | Keros Therapeutics Inc | Stock-Other | 0.87% | — | +9.64% | |
| 29 | AQST | Aquestive Therapeutics Inc | Stock-Other | 0.86% | -0.91% | +2.22% | |
| 30 | NN | Nextnav Inc | Stock-Other | 0.78% | — | — | |
| 31 | ✓ | Marblegate Acquisition Corp | Stock-Other | 0.44% | — | — | |
| 32 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 0.38% | — | — | |
| 33 | EPD | Enterprise Products Partners | Stock-Energy | 0.34% | -0.32% | EXIT | |
| 34 | ✓ | Adc Therapeutics SA | Stock-Other | 0.33% | -0.58% | — | |
| 35 | ✓ | Inozyme Pharma Inc | Stock-Other | 0.32% | — | — | |
| 36 | GOCOQ | Gohealth Inc-class A | Stock-Other | 0.22% | -0.02% | EXIT | |
| 37 | MRKR | Marker Therapeutics Inc | Stock-Other | 0.22% | -0.07% | — | |
| 38 | ✓ | Alpha Modus Hldgs Inc | Stock-Other | 0.15% | -0.04% | EXIT | |
| 39 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 0.13% | — | — | |
| 40 | SHFS | Shf Holdings Inc | Stock-Other | 0.11% | -0.02% | — | |
| 41 | CAH | Cardinal Health Inc | Stock-Healthcare | 0.08% | -0.10% | EXIT | |
| 42 | ✓ | Stock-Other | 0.07% | — | — | ||
| 43 | SLND-WS | Legato Merger CORP Ii -cw23 | Stock-Other | 0.04% | -0.01% | — | |
| 44 | NIOBW | Niocorp Developments LTD -28 | Stock-Other | 0.04% | -0.08% | — | |
| 45 | ✓ | Rezolve Ai LTD | Stock-Other | 0.04% | -0.02% | — | |
| 46 | AMODW | Insight Acquisition Co -cw23 | Stock-Other | 0.03% | -0.01% | +56.12% | |
| 47 | ✓ | Marblegate Acquisition CORP | Stock-Other | 0.03% | — | — | |
| 48 | ✓ | Critical Metals CORP | Stock-Other | 0.03% | — | — | |
| 49 | BKSY-WS | Blacksky Technology -cw24 | Stock-Other | 0.01% | — | — | |
| 50 | OPTXW | Omnilit Acquisition Cl A -23 | Stock-Other | 0.01% | -0.23% | EXIT |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | NCDL | Nuveen Churchill Direct Lend | +6.5% | — | Unchanged |
| 2 | TQQQ | Proshares Ultrapro Qqq | +3.2% | NEW | New buy |
| 3 | CVEO | Civeo CORP | +2.6% | NEW | New buy |
| 4 | OBDC | Blue Owl Capital CORP | +2.6% | — | Unchanged |
| 5 | HLLY | Holley Inc | +2.3% | +77.84% | Add |
| 6 | EVCM | Evercommerce Inc | +1.2% | — | Unchanged |
| 7 | MLYS | Mineralys Therapeutics Inc | +1.1% | NEW | New buy |
| 8 | CMPS | Compass Pathways PLC | +0.9% | +604.44% | Add |
| 9 | CMPX | Compass Therapeutics Inc | +0.8% | — | Unchanged |
| 10 | NN | Nextnav Inc | +0.8% | NEW | New buy |
| 11 | RARE | Ultragenyx Pharmaceutical In | +0.6% | +29.60% | Add |
| 12 | 260 | Centessa Pharmaceuticals-adr | +0.6% | +43.18% | Add |
| 13 | PVLA | Palvella Therapeutics Inc | +0.6% | -43.91% | Trim |
| 14 | IRON | Disc Medicine Inc | +0.5% | +16.63% | Add |
| 15 | VRNA | Verona Pharma PLC - Adr | +0.4% | NEW | New buy |
| 16 | ✓ | Marblegate Acquisition Corp | +0.3% | — | Unchanged |
| 17 | EYPT | Eyepoint Inc | +0.2% | +19.47% | Add |
| 18 | ✓ | Alpha Modus Hldgs Inc | +0.2% | NEW | New buy |
| 19 | ✓ | Ikena Oncology Inc | +0.1% | — | Unchanged |
| 20 | ELDN | Eledon Pharmaceuticals Inc | +0.1% | -7.14% | Trim |
| 21 | AQST | Aquestive Therapeutics Inc | +0.1% | +2.22% | Add |
| 22 | SHFS | Shf Holdings Inc | +0.1% | NEW | New buy |
| 23 | TRML | Tourmaline Bio Inc | +0.1% | -3.91% | Trim |
| 24 | RPTX | Repare Therapeutics Inc | +0.1% | — | Unchanged |
| 25 | ETWOGBP | E2open Parent Holdings Inc | +0.1% | — | Unchanged |
| 26 | SGMT | Sagimet Biosciences Inc-a | 0% | +0.34% | Add |
| 27 | KROS | Keros Therapeutics Inc | 0% | +9.64% | Add |
| 28 | ✓ | Adc Therapeutics SA | 0% | — | Unchanged |
| 29 | PLMKW | Plum Acquisition Corp. IV | 0% | EXIT | Sold out |
| 30 | OPTX | Syntec Optics Holdings Inc | 0% | EXIT | Sold out |
| 31 | ✓ | Alpha Partners Technology Merg | -0.1% | EXIT | Sold out |
| 32 | ✓ | Rezolve Ai LTD | -0.1% | — | Unchanged |
| 33 | ✓ | -0.1% | — | Unchanged | |
| 34 | CNTX | Context Therapeutics Inc | -0.1% | +15.89% | Add |
| 35 | ✓ | Engene Holdings Inc | -0.1% | +3.78% | Add |
| 36 | GTLB | Gitlab Inc-cl A | -0.1% | EXIT | Sold out |
| 37 | ✓ | -0.2% | EXIT | Sold out | |
| 38 | MRKR | Marker Therapeutics Inc | -0.2% | — | Unchanged |
| 39 | OHI | Omega Healthcare Investors, Inc. | -0.2% | EXIT | Sold out |
| 40 | CNDT | Conduent Inc | -0.3% | +1.28% | Add |
| 41 | TNGX | Tango Therapeutics Inc | -0.3% | +22.49% | Add |
| 42 | ✓ | Inozyme Pharma Inc | -0.4% | — | Unchanged |
| 43 | ✓ | -0.4% | EXIT | Sold out | |
| 44 | MREO | Mereo Biopharma Group Pl-adr | -0.5% | EXIT | Sold out |
| 45 | CGEM | Cullinan Therapeutics Inc | -0.7% | +2.74% | Add |
| 46 | LRMR | Larimar Therapeutics Inc | -0.8% | +2.69% | Add |
| 47 | ✓ | Acelyrin Inc | -2% | EXIT | Sold out |
| 48 | GOCOQ | Gohealth Inc-class A | -2.4% | -69.86% | Trim |
| 49 | PLRX | Pliant Therapeutics Inc | -7.1% | +7.22% | Add |
| 50 | KVYO | Klaviyo Inc-a | -10.3% | EXIT | Sold out |
According to official SEC Form 13F filings, Blue Owl Capital Holdings LP reported a total U.S. public equity portfolio value of $664.5M across 73 disclosed positions in Q1 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including NCDL, OBDC, CGEM) accounted for 22.5% of total reported equity market value during Q1 2025.
Top New Position Initiated
TQQQ
市值: $10.0M
Top Position Liquidated / Trimmed
KVYO
前期市值: $44.5M
During Q1 2025, Blue Owl Capital Holdings LP's top holdings by market value included NCDL (22.1%)、OBDC (9.7%)、CGEM (6.0%). The largest single position, NCDL, represented 22.1% of total portfolio value.
In Q1 2025, Blue Owl Capital Holdings LP made 37 total portfolio adjustments, initiating 7 new buys, adding to 16 positions, trimming 4 holdings, and fully liquidating 10 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.